JHEP Reports最新文献

筛选
英文 中文
Skeletal Muscle Loss with Atezolizumab-Bevacizumab versus Lenvatinib in Unresectable HCC. 阿特唑单抗-贝伐单抗与Lenvatinib治疗不可切除HCC的骨骼肌损失。
IF 8.7 1区 医学
JHEP Reports Pub Date : 2026-11-13 DOI: 10.1016/j.jhepr.2026.102100
Toshinori Toyota, Haruki Uojima, Makoto Chuma, Satoshi Narahara, Jun Kawabata, Takanori Suzuki, Shuichiro Iwasaki, Satoshi Kobayashi, Masahiro Kobayashi, Munenori Honda, Hisashi Hidaka, Yoshitaka Arase, Teppei Matsui, Tsunamasa Watanabe, Hironao Okubo, Tatehiro Kagawa, Hidenori Nagai, Kentaro Matsuura, Manabu Morimoto, Yasuhito Tanaka
{"title":"Skeletal Muscle Loss with Atezolizumab-Bevacizumab versus Lenvatinib in Unresectable HCC.","authors":"Toshinori Toyota, Haruki Uojima, Makoto Chuma, Satoshi Narahara, Jun Kawabata, Takanori Suzuki, Shuichiro Iwasaki, Satoshi Kobayashi, Masahiro Kobayashi, Munenori Honda, Hisashi Hidaka, Yoshitaka Arase, Teppei Matsui, Tsunamasa Watanabe, Hironao Okubo, Tatehiro Kagawa, Hidenori Nagai, Kentaro Matsuura, Manabu Morimoto, Yasuhito Tanaka","doi":"10.1016/j.jhepr.2026.102100","DOIUrl":"https://doi.org/10.1016/j.jhepr.2026.102100","url":null,"abstract":"<p><strong>Background & aims: </strong>Skeletal muscle loss is a recognized prognostic factor in hepatocellular carcinoma (HCC). However, whether skeletal muscle loss during systemic therapy reflects treatment-related effects rather than tumor progression remains unclear. This study evaluated treatment-specific muscle loss and its prognostic impact.</p><p><strong>Methods: </strong>We retrospectively analyzed a prospective multicenter cohort of patients with unresectable HCC treated with lenvatinib (LEN) or atezolizumab plus bevacizumab (ATZ-BEV). Skeletal muscle index (SMI) was measured by computed tomography at baseline and 6 months, and a ≥5% decrease was defined as significant loss. Inverse probability of treatment weighting (IPTW) adjusted baseline differences. The primary endpoint was change in SMI over 6 months between treatments among patients without progression within 6 months. Secondary endpoints assessed associations of muscle loss with overall survival (OS) and progression-free survival (PFS) using a 6-month landmark analysis.</p><p><strong>Results: </strong>A total of 179 patients with disease control at 6 months were included. SMI decline was significantly greater in the LEN group than in the ATZ-BEV group both before and after IPTW adjustment (-6.4% vs -0.6%, P=0.017; -6.4% vs -1.0%, P=0.036). A ≥5% SMI reduction occurred in 52.8% of LEN-treated patients and 38.5% of ATZ-BEV-treated patients. In IPTW-adjusted analysis, ATZ-BEV was independently associated with a lower risk of significant muscle loss (odds ratio 0.45, 95% confidence interval 0.22-0.95; P=0.036). In the landmark analysis, treatment-related skeletal muscle loss was not associated with PFS but was significantly associated with worse OS both before (P=0.002) and after IPTW adjustment (P=0.008).</p><p><strong>Conclusion: </strong>Treatment-specific skeletal muscle loss differs between regimens and is associated with worse overall survival in unresectable HCC.</p><p><strong>Impact and implications: </strong>Skeletal muscle loss during systemic therapy is increasingly recognized as an important determinant of prognosis in patients with unresectable hepatocellular carcinoma. In this multicenter study, atezolizumab-bevacizumab was associated with a significantly lower risk of treatment-related skeletal muscle loss than lenvatinib after adjustment for baseline characteristics. These findings suggest that preservation of skeletal muscle should be considered when selecting systemic therapies and monitoring patients during treatment. Although confirmation in prospective studies is required, our results provide clinically relevant evidence supporting routine assessment of skeletal muscle and the development of interventions aimed at preventing treatment-related skeletal muscle loss.</p>","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":" ","pages":"102100"},"PeriodicalIF":8.7,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149406246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Age-specific histological features of severe alpha-1 antitrypsin deficiency-associated liver disease (Pi*ZZ genotype) ☆. 严重α -1抗胰蛋白酶缺乏相关性肝病(Pi*ZZ基因型)的年龄特异性组织学特征
IF 8.7 1区 医学
JHEP Reports Pub Date : 2026-11-11 DOI: 10.1016/j.jhepr.2026.102099
Malin Fromme, Sophie Collardeau-Frachon, Dania El Abyad, Mousa Mobarki, Emmanuel Gonzales, Emmanuel Jacquemin, Catherine Guettier, Marion Bouchecareilh, Laura Rademacher, Fabienne Klebingat, Barbora Mikulkova, Rainer Ganschow, Heike Bantel, Sabina Janciauskiene, Mattias Mandorfer, Elmar Aigner, Ekkehard Sturm, Matthias Christian Reichert, Georg Friedrich Vogel, Jef Verbeek, Aleksander Krag, Piotr Socha, Alain Lachaux, Olivier Govaere, Tania Roskams, Helmut Denk, Mathias Ruiz, Pavel Strnad
{"title":"Age-specific histological features of severe alpha-1 antitrypsin deficiency-associated liver disease (Pi*ZZ genotype) <sup>☆</sup>.","authors":"Malin Fromme, Sophie Collardeau-Frachon, Dania El Abyad, Mousa Mobarki, Emmanuel Gonzales, Emmanuel Jacquemin, Catherine Guettier, Marion Bouchecareilh, Laura Rademacher, Fabienne Klebingat, Barbora Mikulkova, Rainer Ganschow, Heike Bantel, Sabina Janciauskiene, Mattias Mandorfer, Elmar Aigner, Ekkehard Sturm, Matthias Christian Reichert, Georg Friedrich Vogel, Jef Verbeek, Aleksander Krag, Piotr Socha, Alain Lachaux, Olivier Govaere, Tania Roskams, Helmut Denk, Mathias Ruiz, Pavel Strnad","doi":"10.1016/j.jhepr.2026.102099","DOIUrl":"https://doi.org/10.1016/j.jhepr.2026.102099","url":null,"abstract":"<p><strong>Background: </strong>Liver disease in severe alpha-1 antitrypsin (AAT) deficiency (Pi*ZZ genotype) displays a biphasic pattern with peaks in early childhood and later adulthood. The aim was to compare the histological liver phenotype in children and adults with Pi*ZZ genotype.</p><p><strong>Methods: </strong>Specimens from 67 Pi*ZZ adults and 48 Pi*ZZ children from six European countries were independently scored by two histopathologists in a blinded fashion. Sequential multiplex immunofluorescence staining (COMET) quantified histological features in a representative adult and pediatric sample.</p><p><strong>Results: </strong>Pediatric Pi*ZZ samples originated more often from liver transplantation (64.6 vs. 21.2%, p < .001). Compared to adults, children presented a significantly higher fibrosis stage according to METAVIR (4.0 vs. 2.5, p < .001). Liver steatosis was somewhat more prevalent in Pi*ZZ adults, while bile plugs and duct paucity were significantly more common in Pi*ZZ children (bile plugs: 43.8 vs. 10.4%, p < .001; duct paucity 58.3 vs. 1.5%, p < .001) even when adjusted for fibrosis stage. Age-based assessment of pediatric cohort (6-17 years, 1-5 years, < 1 year) revealed that cirrhosis was more common in older age groups than in infants (64.7 vs. 75.0 vs. 30.8%). Youngest children displayed less AAT accumulation and less frequently had larger aggregates, while preschoolers had the highest liver injury markers. >70% of children received ursodeoxycholic acid (UDCA) and the treated children had a more pronounced fibrosis, cholestasis and duct paucity. Multiplex staining confirmed the loss of mature bile ducts while retaining hepatocyte zonation in pediatric vs adult.</p><p><strong>Conclusion: </strong>Our study reveals unique histological patterns in Pi*ZZ children and adults. It provides basis for further mechanistic studies and may guide selection into clinical trials.</p><p><strong>Impact and implications: </strong>Alpha-1 antitrypsin deficiency (AATD) is an inherited disorder that predisposes to liver disease and can manifest in early childhood as well as late adulthood. Our work systematically compares a large international set of pediatric and adult liver specimen and demonstrates age-specific histological features. Our results should support patient counseling (i.e. in case of late diagnosis of pediatric disease) and management including selection of patients for clinical trials.</p>","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":" ","pages":"102099"},"PeriodicalIF":8.7,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149394292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of two TM6SF2 variants on steatotic liver disease, cirrhosis, and hepatocellular carcinoma. 两种TM6SF2变异对脂肪变性肝病、肝硬化和肝细胞癌的影响
IF 8.7 1区 医学
JHEP Reports Pub Date : 2026-11-11 DOI: 10.1016/j.jhepr.2026.102098
Lærke Kristine Kyhl, Tim Møller Eyrich, Søren Nicolaj Rønborg, Anne-Sofie Seidelin, Anne Tybjærg-Hansen, Stefan Stender
{"title":"Effect of two TM6SF2 variants on steatotic liver disease, cirrhosis, and hepatocellular carcinoma.","authors":"Lærke Kristine Kyhl, Tim Møller Eyrich, Søren Nicolaj Rønborg, Anne-Sofie Seidelin, Anne Tybjærg-Hansen, Stefan Stender","doi":"10.1016/j.jhepr.2026.102098","DOIUrl":"https://doi.org/10.1016/j.jhepr.2026.102098","url":null,"abstract":"<p><strong>Background & aims: </strong>While the TM6SF2 E167K variant is a known driver of steatotic liver disease, the impact of the rarer L156P variant and the cumulative effect of multiple TM6SF2 risk alleles remains undefined.</p><p><strong>Methods: </strong>We analyzed 393,742 individuals from the UK Biobank, 239,967 from All of Us, and 113,015 from a Copenhagen Cohort. We assessed MRI-measured proton density fat fraction (PDFF), plasma lipids, alanine transaminase (ALT), cirrhosis, and hepatocellular carcinoma (HCC) as a function of TM6SF2 E167K and L156P genotype combinations. Finally, we tested the associations between other rare missense variants in TM6SF2 and PDFF.</p><p><strong>Results: </strong>In the UK Biobank, median PDFF increased from 3.0% in non-carriers (EE/LL) to 6.3% in E167K homozygotes (KK/LL), 9.3% in compound heterozygotes (EK/LP), and 20.3% in L156P homozygotes (EE/PP). Compared to non-carriers, cirrhosis risk increased stepwise to odds ratios (ORs) of 3.02 (95% CI: 2.05-4.26) in E167K homozygotes, 4.96 (3.03-7.62) in compound heterozygotes, peaking at 9.96 (2.42-27.1) in L156P homozygotes. A similar pattern was observed for HCC with ORs of 7.81 (5.03-11.55) in E167K homozygotes, 8.63 (4.28-15.4) in compound heterozygotes, and 10.12 (0.57-46.7) in L156P homozygotes. These ORs were mirrored by stepwise decreases in LDL cholesterol and triglycerides. Results were validated in All of Us and the Copenhagen Cohort. A broader screen identified three additional rare TM6SF2 missense variants associated with PDFF (A128V, P216L, and F336C).</p><p><strong>Conclusions: </strong>TM6SF2 L156P was associated with increased hepatic fat content and increased risk of cirrhosis and HCC with effect sizes exceeding E167K. The high risk observed in compound heterozygotes suggests a cumulative loss-of-function effect.</p><p><strong>Impact and implications: </strong>Although the TM6SF2 E167K variant is a widely studied risk factor for steatotic liver disease (SLD), the clinical impact of the rarer L156P variant, and the combined effect of these two variants have remained uncharacterized. These findings are important for hepatologists, clinical geneticists, and pharmaceutical researchers, as they show that L156P confers an even higher risk of progressive liver disease than E167K, particularly in the homozygous or compound heterozygous states. Practically, these results can guide the design of multi-variant genetic screening panels and help clinicians identify and stratify high-risk patients for early, targeted cirrhosis and HCC surveillance; however, given the rarity of these genotypes and our cohorts' European ancestry, broad clinical guidelines must await further validation in larger, multi-ethnic cohorts.</p>","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":" ","pages":"102098"},"PeriodicalIF":8.7,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149394293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient Awareness and Disease Burden in MASLD: A Large-Scale Survey. MASLD患者意识与疾病负担:一项大规模调查。
IF 8.7 1区 医学
JHEP Reports Pub Date : 2026-11-05 DOI: 10.1016/j.jhepr.2026.102081
Gabriele Di Maria, Marco Bartoli, Domenica Matranga, Calogero Cammà, Massimiliano Conforti, Salvatore Petta
{"title":"Patient Awareness and Disease Burden in MASLD: A Large-Scale Survey.","authors":"Gabriele Di Maria, Marco Bartoli, Domenica Matranga, Calogero Cammà, Massimiliano Conforti, Salvatore Petta","doi":"10.1016/j.jhepr.2026.102081","DOIUrl":"https://doi.org/10.1016/j.jhepr.2026.102081","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background and aims: &lt;/strong&gt;A global international Delphi consensus of MASLD experts prioritised patient education and awareness as a key research domain, explicitly calling for population-based surveys to quantify knowledge gaps and guide targeted interventions. Commissioned by the EpaC ETS patient association, this study described patients' characteristics regarding MASLD awareness and health literacy. Secondary aim was to assess the psychometric properties and construct structure of the survey instrument.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This cross-sectional study enrolled 460 Italian adults with self-reported physician-diagnosed MASLD. The eight-domain questionnaire covered disease awareness, nomenclature familiarity, diagnostic pathway, follow-up, treatment knowledge, lifestyle adherence, supplement and pharmacotherapy use, and economic burden. Psychometric validation of 40 Likert items employed exploratory and confirmatory factor analysis and MIMIC modelling.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Pre-diagnostic awareness was strikingly low: 59.8% had never heard of MASLD; familiarity with current nomenclature was negligible (MASLD 8.5%, MASH 9.8%). Critical misconceptions included failure to recognise diabetes as a risk factor (43.5%), belief that transaminases are always elevated (41.5%), and that disease progression requires elevated ALT (51.5%). Symptom burden was high and significantly greater in women across all domains (p&lt;0.001). Despite appropriate physician counselling, three in four patients (75.7%) did not meet the recommended &gt;= 150 min/week and 26.1% were entirely inactive. Supplements were used by 27.6%, largely self-prescribed; pharmacotherapy by 11.7%, of whom 50.0% received ursodeoxycholic acid - not guideline-recommended. Direct economic burden affected 64.6% of patients. Psychometric validation identified five latent dimensions (symptom burden, disease knowledge, reversibility beliefs, lifestyle efficacy beliefs, extrahepatic risk awareness) with acceptable model fit (CFI=0.917, RMSEA=0.069) and good-to-excellent reliability (omega 0.79-0.93). MIMIC modelling showed that symptom burden was driven by female sex and by depression, while cognitive dimensions were determined primarily by educational attainment and, to a lesser extent, by obesity.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Italian patients with self-reported physician diagnosis of MASLD harbour profound educational deficits, a marked attitude-practice gap, and partly guideline-discordant pharmacotherapy. The five-domain instrument provides a candidate framework for stratified educational interventions, for which external validation in an independent cohort is a prerequisite.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Impact and implications: &lt;/strong&gt;A global Delphi consensus of MASLD experts identified patient education and awareness as a priority research domain and explicitly called for population-based surveys to quantify knowledge gaps, yet patient-level European data remain scarce; th","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":" ","pages":"102081"},"PeriodicalIF":8.7,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149342245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Precision medicine in patients with advanced biliary tract cancer. 晚期胆道癌患者的精准医疗。
IF 8.7 1区 医学
JHEP Reports Pub Date : 2026-11-04 DOI: 10.1016/j.jhepr.2026.102088
Leony Antoun, Alice Boilève, Noémie Simon-Tillaux, Anthony Tarabay, Etienne Rouleau, Elsa El Rawadi, Roland Eid, Ludovic Lacroix, Marine Valery, Valérie Boige, Peggy Dartigues, Mohamed-Amine Bani, Cristina Smolenschi, Imene Deneche, Jean-Yves Scoazec, Michel Ducreux, Antoine Hollebecque, David Malka
{"title":"Precision medicine in patients with advanced biliary tract cancer.","authors":"Leony Antoun, Alice Boilève, Noémie Simon-Tillaux, Anthony Tarabay, Etienne Rouleau, Elsa El Rawadi, Roland Eid, Ludovic Lacroix, Marine Valery, Valérie Boige, Peggy Dartigues, Mohamed-Amine Bani, Cristina Smolenschi, Imene Deneche, Jean-Yves Scoazec, Michel Ducreux, Antoine Hollebecque, David Malka","doi":"10.1016/j.jhepr.2026.102088","DOIUrl":"https://doi.org/10.1016/j.jhepr.2026.102088","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background & aims: &lt;/strong&gt;To determine whether a program of molecular profiling and matching targeted therapy in advanced biliary tract cancer improves patient outcomes.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;We reviewed all patients with advanced biliary tract cancer treated in our institution between 2015 and 2021 with a molecular profile available. We compared overall survival and growth modulation index (study primary endpoints) according to the absence or presence of targetable alterations and to the treatment received after profiling.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Of 313 patients with a molecular profile, 146 (46.6%) harbored at least one targetable alteration; 77 patients (24.6%) received molecular targeted agents (molecularly matched therapy group), 37 (11.8%) received conventional therapy (unmatched therapy group), and 32 (10.2%) were not treated. No targetable alterations were found in 167 patients (53.4%); 126 patients (40.3%) received conventional therapy (no-alteration group) and 41 (13.1%) were not treated. Overall survival was longer in the molecularly matched therapy group (median, 28.0 months [95%CI 24.8-36.7]) than in unmatched therapy (18.0 months [95%CI 15.7-26.6]; HR 1.80 [95%CI 1.17-2.78]; p=0.011) and no-alteration (22.9 months [95%CI 19.7-26.3]; HR 1.55 [95%CI 1.12-2.16]; p=0.008) groups. A growth modulation index ≥1.33 was observed in 49% (CI, 38%-61%) of the patients in the molecularly matched therapy group versus 34% (CI, 26%-42%) in the unmatched therapy and no-alteration groups combined (p=0.024). Molecularly matched therapy group patients had better progression-free survival and clinical benefit rate than patients in the unmatched therapy and no-alteration groups.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Identifying targetable alterations and providing molecularly matching therapy in 25% of patients was associated with improved outcomes in advanced biliary tract cancer.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Impact and implications: &lt;/strong&gt;Molecular profiling has become an increasingly important component of the management of advanced biliary tract cancer (BTC), a disease characterized by substantial molecular heterogeneity and a growing number of actionable alterations. In this retrospective study of 313 patients with advanced BTC who underwent molecular profiling, nearly half harbored an alteration considered targetable according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Patients who received a matched molecular targeted therapy had longer overall and progression-free survival, as well as higher growth modulation index, objective response, and clinical benefit rates, than patients treated with conventional therapy, whether or not a targetable alteration was identified. These findings support the clinical relevance of identifying actionable alterations and ensuring access to matched therapies in advanced BTC. The results are particularly relevant to physicians involved in the multidisciplinary managemen","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":" ","pages":"102088"},"PeriodicalIF":8.7,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149333962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Porto-sinusoidal vascular disorder-type lesions in patients with early fibrotic stages of metabolic dysfunction-associated steatotic liver disease. 代谢功能障碍相关脂肪变性肝病早期纤维化期患者的门窦血管紊乱型病变
IF 8.7 1区 医学
JHEP Reports Pub Date : 2026-11-03 DOI: 10.1016/j.jhepr.2026.102089
Diederick J van Doorn, Lotte Schoenmakers, Sebastiaan de Jager, Marten A Lantinga, Adriaan G Holleboom, Joost P H Drenth, Wilhelmus J Kwanten, Sven Francque, R Bart Takkenberg, Ann Driessen, Joanne Verheij
{"title":"Porto-sinusoidal vascular disorder-type lesions in patients with early fibrotic stages of metabolic dysfunction-associated steatotic liver disease.","authors":"Diederick J van Doorn, Lotte Schoenmakers, Sebastiaan de Jager, Marten A Lantinga, Adriaan G Holleboom, Joost P H Drenth, Wilhelmus J Kwanten, Sven Francque, R Bart Takkenberg, Ann Driessen, Joanne Verheij","doi":"10.1016/j.jhepr.2026.102089","DOIUrl":"https://doi.org/10.1016/j.jhepr.2026.102089","url":null,"abstract":"<p><strong>Background and objective: </strong>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a rising cause of chronic liver disease. Liver stiffness measurement (LSM) to assess disease stage is gaining popularity but can demonstrate heterogeneous results in clinical practice. Moreover, portal hypertension may develop early in MASLD in the absence of cirrhosis. These observations may be partially explained by features not assessed in the current NASH-CRN liver biopsy staging, including features of porto-sinusoidal vascular disorder (PSVD).</p><p><strong>Methods: </strong>We conducted a retrospective cohort study in patients with MASLD who underwent biopsy between 2015 and 2022. All biopsies with NASH-CRN F0-F2 were screened for eligibility and revised in consensus by two expert liver pathologists. Primary objective was to assess the presence and severity of PSVD-type lesions. Secondary objectives included the grading of perisinusoidal fibrosis and to correlate histological features with LSM.</p><p><strong>Results: </strong>We included 136 patients [60% male, median age 50y] with a median BMI of 30 kg/m<sup>2</sup>, 15% having F1 fibrosis and 85% F2 fibrosis. Median LSM (available in 54%) was 8.2 kPa. Portal venule stenosis affecting ≥50% of portal tracts was present in 26% of biopsies, and muscularisation of portal venules was present in 21% of biopsies. Perisinusoidal fibrosis was present in 97% of biopsies, respectively mild, moderate, and severe in 62%, 32%, and 3%. PSVD-type lesions did not correlate with LSM, but LSM did correlate with the degree of perisinusoidal fibrosis.</p><p><strong>Conclusion: </strong>Portal venule stenosis (≥50%) and muscularisation of portal venules, both major criteria associated with PSVD, were found in 26% and 21% biopsies, respectively. Furthermore, the extent of perisinusoidal fibrosis correlates with liver stiffness and could explain the heterogeneity of LSM in MASLD.</p>","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":" ","pages":"102089"},"PeriodicalIF":8.7,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149321326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Single-cell profiling reveals monocyte mitochondrial dysfunction in patients with cirrhosis progressing to acute-on-chronic liver failure. 单细胞分析显示单核细胞线粒体功能障碍在肝硬化进展为急性慢性肝衰竭的患者。
IF 8.7 1区 医学
JHEP Reports Pub Date : 2026-11-03 DOI: 10.1016/j.jhepr.2026.102087
Theresa Hildegard Wirtz, Sara Palomino-Echeverria, Maike Rebecca Pollmanns, Estefanía Huergo, Felix Schreibing, Johanna Reißing, Cristina Sánchez-Garrido, Cristina López-Vicario, Ana Maria Aransay, Maurizio Baldassare, Giacomo Zaccherini, Enrico Pompili, Martin Sebastian McCoy, Frank Erhard Uschner, Sabine Klein, Wenyi Gu, Robert Schierwagen, Shantha Valainathan, Annabelle Verbeeck, Daniela Campion, Ilaria Giovo, Kai Markus Schneider, Alexander Koch, Rafael Kramann, Tony Bruns, Narsis Kiani, Linsey Stiles, Paolo Caraceni, Carlo Alessandria, Richard Moreau, Jonel Trebicka, Joan Clària, Núria Planell, Pierre-Emmanuel Rautou, Christian Trautwein, David Gomez-Cabrero
{"title":"Single-cell profiling reveals monocyte mitochondrial dysfunction in patients with cirrhosis progressing to acute-on-chronic liver failure.","authors":"Theresa Hildegard Wirtz, Sara Palomino-Echeverria, Maike Rebecca Pollmanns, Estefanía Huergo, Felix Schreibing, Johanna Reißing, Cristina Sánchez-Garrido, Cristina López-Vicario, Ana Maria Aransay, Maurizio Baldassare, Giacomo Zaccherini, Enrico Pompili, Martin Sebastian McCoy, Frank Erhard Uschner, Sabine Klein, Wenyi Gu, Robert Schierwagen, Shantha Valainathan, Annabelle Verbeeck, Daniela Campion, Ilaria Giovo, Kai Markus Schneider, Alexander Koch, Rafael Kramann, Tony Bruns, Narsis Kiani, Linsey Stiles, Paolo Caraceni, Carlo Alessandria, Richard Moreau, Jonel Trebicka, Joan Clària, Núria Planell, Pierre-Emmanuel Rautou, Christian Trautwein, David Gomez-Cabrero","doi":"10.1016/j.jhepr.2026.102087","DOIUrl":"https://doi.org/10.1016/j.jhepr.2026.102087","url":null,"abstract":"<p><strong>Background & aims: </strong>Patients with acute decompensation (AD) of cirrhosis are at a high risk of developing acute-on-chronic liver failure (ACLF), a syndrome characterized by multi-organ failure and high short-term mortality. Prospective studies addressing the cellular mechanisms that drive the transition from AD to ACLF are lacking. In this study, we aimed to determine whether peripheral immune cell subsets at hospital admission predict the progression from AD to ACLF and to delineate underlying molecular mechanisms.</p><p><strong>Methods: </strong>We prospectively enrolled 63 patients with AD and 15 healthy donors across five European centres, with a 90-day follow-up. Single-cell RNA sequencing was performed on peripheral blood mononuclear cells (PBMCs) from 16 patients with distinct trajectories and 4 controls.</p><p><strong>Results: </strong>Progression to ACLF was associated with expansion of classical monocytes, particularly subcluster \"C2\", which specifically displayed impaired energy metabolism with reduced oxidative phosphorylation (p<0.001). A C2-derived gene signature (18 genes) was enriched in two large international whole-blood cohorts (PREDICT, n=689; ACLARA, n=521), particularly in patients with bacterial infections, those developing ACLF, and non-survivors (p<0.001). Functional validation by respirometry in an independent AD cohort confirmed declining monocyte Complex IV-dependent oxygen consumption in patients with pre-ACLF (p<0.05).</p><p><strong>Conclusions: </strong>We identified and validated a distinct monocyte subpopulation with defective energy metabolism in patients with AD with poor outcomes, supporting a link between monocyte bioenergetic dysfunction and ACLF development. Impact and Implications:The cellular mechanisms that drive progression from acute decompensation (AD) to acute-on-chronic liver failure (ACLF) remain poorly understood, limiting the development of effective strategies for therapeutic intervention. By integrating prospective single-cell transcriptomics, functional bioenergetic analyses, and validation in independent multicentre cohorts, we identified a distinct monocyte subset characterized by impaired oxidative phosphorylation that is associated with subsequent ACLF development. These findings are relevant to clinicians and researchers because they suggest that immune-metabolic dysfunction emerges before overt ACLF and may contribute to disease progression. While further mechanistic and prospective validation studies are required, our results provide a framework for the investigation of monocyte bioenergetics as a potential therapeutic target in patients with decompensated cirrhosis.</p>","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":" ","pages":"102087"},"PeriodicalIF":8.7,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149321327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A novel preclinical platform to study FGFR2 fusion-driven cholangiocarcinoma☆. 研究FGFR2融合驱动的胆管癌的一个新的临床前平台
IF 8.7 1区 医学
JHEP Reports Pub Date : 2026-11-03 DOI: 10.1016/j.jhepr.2026.102090
Alexandra Wolf, Matias Facciuto, Melissa Damiecki, Emily R Bramel, Eric Park, Sara E Young, Miguel Torres, Shalini Nath, Vincenzo Mazzaferro, Myron Schwartz, Amaia Lujambio, Benjamin D Hopkins, Alexander M Tsankov, Anna Tocheva, Daniela Sia
{"title":"A novel preclinical platform to study FGFR2 fusion-driven cholangiocarcinoma<sup>☆</sup>.","authors":"Alexandra Wolf, Matias Facciuto, Melissa Damiecki, Emily R Bramel, Eric Park, Sara E Young, Miguel Torres, Shalini Nath, Vincenzo Mazzaferro, Myron Schwartz, Amaia Lujambio, Benjamin D Hopkins, Alexander M Tsankov, Anna Tocheva, Daniela Sia","doi":"10.1016/j.jhepr.2026.102090","DOIUrl":"https://doi.org/10.1016/j.jhepr.2026.102090","url":null,"abstract":"<p><strong>Background & aims: </strong>FGFR2 fusions represent the most frequent genetic alteration in intrahepatic cholangiocarcinoma (iCCA). However, clinical responses to FGFR inhibitors are suboptimal. A major limitation is that preclinical models do not mimic the immunobiology of human FGFR2-driven iCCA. We developed an autochthonous and immunocompetent FGFR2 fusion-driven mouse model.</p><p><strong>Methods: </strong>Using the hydrodynamic tail-vein injection method, we generated a mouse model harboring the FGFR2-PPHLN1 fusion (with or without the V565F resistance mutation) in combination with activated YAP1, and established 2D lines and 3D organoids. We characterized tumors using bulk and single cell RNA-sequencing (n=3), spectral cytometry (n=3-7/group), and performed cross-species analysis using 411 human samples. Tumor-associated neutrophils (TAN) were depleted in vivo using an anti-murine Ly6G antibody. In vitro and in vivo drug treatment with FGFR inhibitors and anti-PD-L1 was performed.</p><p><strong>Results: </strong>FGFR2-driven murine tumors were molecularly and immunologically similar to human iCCA, with selective accumulation of TAN and impaired T cell infiltration. scRNA-seq identified pro-tumorigenic and immunomodulatory TAN subsets while In vivo TAN depletion significantly prolonged survival (log-rank p=0.009) and led to increased CD8<sup>+</sup> T cells infiltration (p=0.007). 3D organoids reproduced clinical responses to irreversible FGFR inhibitors, while showing a sustained response to the reversible inhibitor derazantinib in presence of the V565F mutation (IC50=5.190uM). In vivo derazantinib reduced tumor number (unadj. p=0.03) and marginally prolonged survival (unadj. p=0.052) whereas no statistically significant benefit of anti-PD-L1 was detected, either alone or in combination.</p><p><strong>Conclusions: </strong>Our mouse model faithfully recapitulates the immunobiology and therapeutic sensitivities of the human disease. Inter-species and cross-species analyses suggest a critical role of FGFR2 fusions in shaping a cold tumor microenvironment with selective accumulation of TAN in both humans and mice.</p><p><strong>Impact and implications: </strong>This study develops a clinically-relevant mouse model of FGFR2-driven iCCA for future translational studies. Accumulation of pro-tumorigenic and immunomodulatory TAN along with poor sensitivity to immune checkpoint inhibitors suggests the need of designing alternative strategies harnessing the unique immunosuppressive nature of these tumors.</p>","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":" ","pages":"102090"},"PeriodicalIF":8.7,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149321323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrating patient advocacy into hepatology practice - Current perspective and future directions. 将患者倡导纳入肝病学实践-当前观点和未来方向。
IF 8.7 1区 医学
JHEP Reports Pub Date : 2026-11-02 DOI: 10.1016/j.jhepr.2026.102065
Clémence Ramier, Sophie Penisson, Janne Suykens, Luciana Holtz, Manon Allaire, Aurélie Plessier
{"title":"Integrating patient advocacy into hepatology practice - Current perspective and future directions.","authors":"Clémence Ramier, Sophie Penisson, Janne Suykens, Luciana Holtz, Manon Allaire, Aurélie Plessier","doi":"10.1016/j.jhepr.2026.102065","DOIUrl":"https://doi.org/10.1016/j.jhepr.2026.102065","url":null,"abstract":"<p><p>The importance of patient advocacy in hepatology is indicative of a more general shift towards patient-centred and participatory healthcare. Liver diseases represent a significant global health burden, characterised by clinical complexity, a wide range of associated conditions, the invisible nature of disease progression, and frequent associations with stigma and social vulnerability. These challenges contribute to delayed diagnosis, care inequalities, and non-optimal patient engagement, highlighting the need for more support and advocacy frameworks. The concept of patient advocacy encompasses a wide range of actions designed to empower patients, improve health literacy, and ensure that patients' perspectives are integrated into care, research, and policy. It encompasses a diverse range of stakeholders, including healthcare professionals, patients, caregivers, and patient organisations, operating at various levels, namely clinical, community, and institutional. By encouraging shared decision-making and providing support to patients through often complex care pathways, patient advocacy contributes to better alignment between medical management and patients' needs. The growing recognition of patient-reported outcomes has further underscored the significance of incorporating the patient voice into clinical practice and research. Concurrently, patient participation in research and health policy enhances the relevance of scientific outputs and fosters more equitable healthcare systems. A range of practical tools has been developed for the purpose of enhancing patient engagement and empowerment. These include patient education programmes, patient journey mapping, and coordinated care pathways. However, despite this progress, significant challenges remain, including ongoing health disparities, disease-related stigma, and limited collaboration between stakeholders. The necessity of strengthening patient advocacy in hepatology is fundamental to the enhancement of clinical outcomes and the optimisation of care management for patients.</p>","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":" ","pages":"102065"},"PeriodicalIF":8.7,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149321324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New CLA3+/4 scores predict outcomes in MASLD. 新的CLA3+/4评分预测MASLD的预后。
IF 8.7 1区 医学
JHEP Reports Pub Date : 2026-11-02 DOI: 10.1016/j.jhepr.2026.102074
Dong Hyun Kim, Na Hyun Cho, Terry Cheuk-Fung Yip, Salvatore Petta, Elisabetta Bugianesi, Masato Yoneda, Ming-Hua Zheng, Hannes Hagström, Jérôme Boursier, José Luis Calleja, George Boon-Bee Goh, Wah-Kheong Chan, Manuel Romero-Gomez, Arun J Sanyal, Victor de Lédinghen, Philip N Newsome, Jian-Gao Fan, Laurent Castéra, Vincent Wai-Sun Wong, Seung Up Kim, Hye Won Lee
{"title":"New CLA3+/4 scores predict outcomes in MASLD.","authors":"Dong Hyun Kim, Na Hyun Cho, Terry Cheuk-Fung Yip, Salvatore Petta, Elisabetta Bugianesi, Masato Yoneda, Ming-Hua Zheng, Hannes Hagström, Jérôme Boursier, José Luis Calleja, George Boon-Bee Goh, Wah-Kheong Chan, Manuel Romero-Gomez, Arun J Sanyal, Victor de Lédinghen, Philip N Newsome, Jian-Gao Fan, Laurent Castéra, Vincent Wai-Sun Wong, Seung Up Kim, Hye Won Lee","doi":"10.1016/j.jhepr.2026.102074","DOIUrl":"https://doi.org/10.1016/j.jhepr.2026.102074","url":null,"abstract":"<p><strong>Background & aims: </strong>Fibrosis is a major determinant of adverse outcomes in metabolic dysfunction-associated steatotic liver disease (MASLD). We developed and validated two probability scores for advanced fibrosis (≥F3) and cirrhosis (F4)-CLA3+ and CLA4-using controlled attenuation parameter (CAP), liver stiffness (LS) by vibration-controlled transient elastography (VCTE), and alanine aminotransferase (ALT), and evaluated their prognostic values for liver-related events (LREs).</p><p><strong>Methods: </strong>In a 16-center multinational cohort, single-term fractional-polynomial logistic regression models derived CLA3+ and CLA4 probabilities. Prognostic performance was assessed using time-dependent area under the receiver operating characteristic curve (AUROC), Brier score, integrated discrimination improvement (IDI), and serial-change analyses.</p><p><strong>Results: </strong>The derivation cohort included 2,811 biopsied patients; validation included 11,196 patients with baseline VCTE, of whom 8,046 had serial assessments. Derivation AUROCs were 0.84 for CLA3+ and 0.89 for CLA4. In validation, both achieved the highest integrated AUROC (0.83) and lowest integrated Brier scores (0.0078-0.0081) among non-invasive tests, with good calibration. CLA3+ classified 83.1%/10.8%/6.1% as low/intermediate/high risk (5-year LRE 0.4%/1.5%/11.8%; sensitivity 0.72), whereas CLA4 classified 92.0%/3.6%/4.4% (0.5%/4.7%/13.0%; specificity 0.93), with the smallest intermediate-risk groups. IDI favored CLA3+ over Agile3+, whereas CLA4 performed similarly to Agile4. Serial risk categories remained stable in 86.7% for CLA3+ and 93.2% for CLA4, while ≥10-30% decreases were associated with lower LRE risk. Two-step testing reduced intermediate classifications to 3.9% with FIB-4→CLA3+ and 1.4% with FIB-4→CLA4, with a 5-year LRE rate of 8.3% in the rule-in group.</p><p><strong>Conclusions: </strong>CLA3+ and CLA4 provide well-calibrated estimates for advanced fibrosis and cirrhosis using controlled attenuation parameter, liver stiffness, and alanine aminotransferase, with small intermediate-risk groups and prognostically informative serial changes. They may serve as second-line tests within Fibrosis-4 index-based two-step pathways.</p><p><strong>Impact and implications: </strong>Current MASLD care pathways use sequential non-invasive testing to identify patients at risk of advanced fibrosis and liver-related events, but existing composite scores often require multiple clinical inputs and leave substantial intermediate-risk groups. CLA 3+ and CLA 4 use CAP, liver stiffness, and ALT to achieve prognostic performance comparable to Agile scores, while yielding small intermediate-risk groups and informative serial changes. These findings support their potential use as simple second-line tools after FIB-4 and for longitudinal risk assessment in VCTE-based pathways, with relevance to clinical triage and future trial design.</p>","PeriodicalId":14764,"journal":{"name":"JHEP Reports","volume":" ","pages":"102074"},"PeriodicalIF":8.7,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149321325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书